Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases.
According to Immutep, IMP761 was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed to date.
In a statement, Dr. Frédéric Triebel, CSO of Immutep, commented, “IMP761 continues to show a clear immunosuppressive effect in healthy participants challenged with a foreign antigen in an intra-dermal reaction, with durable inhibition of T-cell–mediated responses after a single administration. These first-in-human findings support our mechanistic aim of selectively silencing pathogenic, self-antigen–specific memory T cells via LAG–3 agonism and provide the basis for dose levels to be tested in a future phase II trial in patients with autoimmunity.”
